Австралия - английски - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carbidopa monohydrate, quantity: 33.8 mg (equivalent: carbidopa, qty 31.25 mg); levodopa, quantity: 125 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: glycerol; titanium dioxide; croscarmellose sodium; sucrose; magnesium stearate; polysorbate 80; mannitol; maize starch; povidone; iron oxide red; hypromellose - l.c.e. sandoz 125/31.25/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: povidone; iron oxide yellow; croscarmellose sodium; mannitol; glycerol; maize starch; titanium dioxide; magnesium stearate; polysorbate 80; hypromellose; sucrose; iron oxide red - l.c.e. sandoz 100/25/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg; levodopa, quantity: 75 mg - tablet, film coated - excipient ingredients: polysorbate 80; maize starch; hypromellose; croscarmellose sodium; iron oxide red; titanium dioxide; povidone; magnesium stearate; glycerol; mannitol; sucrose - l.c.e. sandoz 75/18.75/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: hypromellose; mannitol; titanium dioxide; magnesium stearate; povidone; maize starch; sucrose; iron oxide red; glycerol; iron oxide yellow; polysorbate 80; croscarmellose sodium - l.c.e. sandoz 50/12.5/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - albendazole, quantity: 400 mg - tablet, chewable - excipient ingredients: povidone; sodium lauryl sulfate; saccharin sodium; lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; magnesium stearate; maize starch; sunset yellow fcf aluminium lake; flavour - hydatid disease: albendazole is indicated for the treatment of hydatid cysts caused by e. granulosus in adults and children over 6 years of age, where surgical intervention is not feasible because of anatomic site or the presence of multiple cysts. albendazole shows greatest efficacy in the treatment of liver, lung and peritoneal cysts. experience with bone cysts or those in the heart or central nervous system is limited, but cases of successful treatment with prolonged course of albendazole have been reported. albendazole may also be used as an adjunct to surgical excision of hydatid cysts either: 1) prior to surgical intervention, or 2) post-operatively, if pre-operative treatment was too short (less than two separate 28-day cycles) or if viable cysts are found at surgery. larval taeniasis (neurocysticercosis): albendazole is effective in the treatment of neurocysticercosis (ncc) in courses as short as 7 days. other indications: there is also evidence that albendazole is effective against capillaria philippinensis in courses of 10 days.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - albendazole, quantity: 400 mg - tablet, chewable - excipient ingredients: saccharin sodium; sodium lauryl sulfate; croscarmellose sodium; microcrystalline cellulose; povidone; magnesium stearate; maize starch; lactose monohydrate; sunset yellow fcf aluminium lake; flavour - hydatid disease: albendazole is indicated for the treatment of hydatid cysts caused by e. granulosus in adults and children over 6 years of age, where surgical intervention is not feasible because of anatomic site or the presence of multiple cysts. albendazole shows greatest efficacy in the treatment of liver, lung and peritoneal cysts. experience with bone cysts or those in the heart or central nervous system is limited, but cases of successful treatment with prolonged course of albendazole have been reported. albendazole may also be used as an adjunct to surgical excision of hydatid cysts either: 1) prior to surgical intervention, or 2) post-operatively, if pre-operative treatment was too short (less than two separate 28-day cycles) or if viable cysts are found at surgery. larval taeniasis (neurocysticercosis): albendazole is effective in the treatment of neurocysticercosis (ncc) in courses as short as 7 days. other indications: there is also evidence that albendazole is effective against capillaria philippinensis in courses of 10 days.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 150 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 100 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 50 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg); hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; pregelatinised maize starch; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - it is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination.this fixed dose combination is not indicated for initial therapy.